Results 131 to 140 of about 179,181 (243)

Inhibition of KDEL Receptors Remodels the Tumor Microenvironment for T Cell Independent Tumor Regression

Advanced Science, EarlyView.
Inhibition of KDELR2 in a small fraction of tumor cells generates sustainable immunogenic cell death conditions within the tumor microenvironment. These conditions promote the regression of tumors in a T cell independent manner. During regression, macrophages prime T cells that subsequently provide systemic protection against recurrence. The potency of
Shakti P Pattanayak, Hong Wang, Belinda Willard, Timothy A. Chan, William C Merrick, Zheng‐Rong Lu, Boaz Tirosh   +6 more
wiley   +1 more source

Real-World Comparison of PD-1 and PD-L1 Inhibitor Monotherapy in Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression. [PDF]

Cancers (Basel)
Marković F, Bojić Z, Stjepanović M, Kontić M.   +3 more
europepmc   +1 more source

Targeting a Myeloid–Regulatory B Cell Network Reverses Immune Paralysis in Periprosthetic Joint Infections

Advanced Science, EarlyView.
Periprosthetic joint infection establishes a sophisticated immunosuppressive network between CXCR4+ PMN‐MDSCs and Bregs, inducing profound CD8+ T cell paralysis. Alendronate effectively disrupts this CXCR4+ PMN‐MDSC–Breg axis by targeting STAT3, thereby restoring local immune surveillance.
Jintao Wu, Shutao Zhang, Yumin Lin, Juyang Jiao, Zhiwei Fu, Qimin Hong, Ziyi Zhao, Xinhua Qu, Fei Su, Bing Yue   +9 more
wiley   +1 more source

AK5 suppresses breast cancer progression and modulates anti-PD-L1 efficacy via the miR-182-5p/PD-L1 axis. [PDF]

iScience
Sun GS, Li YH, Li L, Fan LL, Yang H, Lu Q, Liu Z, Wang S, Peng JJ.   +8 more
europepmc   +1 more source

Radiation‐Induced Tumor‐Intrinsic LTβR N‐Glycosylation Suppresses Pyroptosis Through TRIM28‐Mediated PCBP2 SUMOylation to Promote Gastric Cancer Radioresistance

Advanced Science, EarlyView.
Radiotherapy triggers LTβR N‐glycosylation, enhancing its overall protein stability and nuclear retention. This accumulation drives TRIM28‐mediated PCBP2 SUMOylation, suppressing pyroptosis and conferring gastric cancer radioresistance. Therapeutically, a targeted nanoplatform (cRGD‐Lipo@EMD) effectively disrupts this regulatory axis, offering a highly
Weijie Zang, Yunlong Ji, Chunwang Zhou, Xiwen Li, Zhuang Lu, Guangze Zhang, Yu Chen, Wanjiang Xue, Yilin Hu   +8 more
wiley   +1 more source

From M7824 to SHR-1701: lessons for dual PD-L1/TGF-β targeting. [PDF]

J Immunother Cancer
Yi M, Li T, Wu K, Dai Z.
europepmc   +1 more source

Biomimetic Macrophage Cell Membrane‐Based Nanoparticles for Effective Treatment of Glioblastoma Through Boron Neutron Capture Therapy Combined With Immunotherapy

Advanced Science, EarlyView.
ABSTRACT Glioblastoma multiforme (GBM) remains largely incurable due to the blood‐brain barrier (BBB) and immunosuppressive microenvironment. While boron neutron capture therapy (BNCT) selectively eradicates tumor cells via 10B(n, α)‐7Li reactions, its clinical potential in GBM is unrealized because of the suboptimal pharmacokinetics of conventional ...
Jiawen Chen, Haoyu You, Hefa Huang, Huihui Chai, Ruize Zhu, Yun Guan, Qisheng Tang, Tianwen Li, Shan Jiang, Houshi Xu, Peng Wang, Yue Wang, Maoyuan Sun, Beining Liu, Zhen Li, Yulai Zeng, Weiqiu Ping, Yanlin Teng, Songlin Yan, Qinghui Li, Long Gu, Tao Sun, Zhifeng Shi   +22 more
wiley   +1 more source

Expression of YTHDF1 and YTHDF2 in lung squamous cell carcinoma and their correlation with PD-L1. [PDF]

J Thorac Dis
Cai L, Qu H, Feng K, He H, Wang F.
europepmc   +1 more source

UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD‐L1 Transcription

Advanced Science, EarlyView.
UBE2O targets CDKL1 for the degradation to upregulate PD‐L1 expression and promotes resistance to radioimmunotherapy in lung cancer, supporting the potential of targeting UBE2O as a promising therapeutic strategy. ABSTRACT Resistance to radioimmunotherapy is one of the primary causes of treatment failure in lung cancer patients; however, the underlying
Huichan Xue, Xiaohua Jie, Zhiwei Liu, Ruoxin Fang, Shuo Wu, Xiaorong Dong, Shuangbing Xu   +6 more
wiley   +1 more source

PD-L1 status on circulating tumor cells: a promising predictor in advanced lung cancer with PD-1/PD-L1 immunotherapies. [PDF]

Eur J Med Res
Wei X, Chen L, Yang Z, Zeng D, Tang D, Jiang J.   +5 more
europepmc   +1 more source